Structural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor
Hidetaka S. Oshima,Akiko Ogawa,Fumiya K. Sano,Hiroaki Akasaka,Tomoyoshi Kawakami,Hiroyuki H. Okaomto,Aika Iwama,Chisae Nagiri,Fan-Yan Wei,Wataru Shihoya,Osamu Nureki
DOI: https://doi.org/10.1101/2024.03.23.586386
2024-03-24
Abstract:Adenosine receptors, expressed across various tissues, play pivotal roles in physiological processes and are implicated in diverse diseases, including neurological disorders and inflammation, highlighting the therapeutic potential of receptor-selective agents. The Adenosine A3 receptor (A R), the last identified adenosine receptor, is also activated by breakdown products of post-transcriptionally modified tRNA and exhibits dual roles in neuron, heart, and immune cells, and is often overexpressed in tumors, making it a target for anticancer therapy. Despite extensive studies on the other adenosine receptors, the structure and activation mechanism of A R, especially by selective agonists like -methyladenosine (m A) and namodenoson, remained elusive. Here, we identified -isopentenyl adenosine (i A), a novel A R-selective ligand, via comprehensive modified adenosine library screening. Cryo-EM analyses of A R-G signaling complexes with two nonselective and three selective agonists revealed the structural basis for A R activation. We further conducted structure-guided engineering of m A-insensitive A R, which would greatly facilitate future discoveries of the physiological functions of the selective activation of A R by modified adenosines. Our results clarify the selective activation of adenosine receptors, providing the basis for future drug discovery.
Biophysics